Christophe Morin

Prof. Christophe Morin

Université Paris Est Créteil
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
CMChristophe Morin
Christophe Morin
Nicolas SimonNicolas Simon
Nicolas Simon
Evidence obtained over the past two decades shows that reactive oxygen species (ROS) are involved in brain lesions, including those due to cerebral ischemia-reperfusion. The mitochondria are the primary intracellular source of ROS, as they generate huge numbers of oxidative-reduction reactions and use massive amounts of oxygen. When anoxia is followed promptly by reperfusion, the resulting increase in oxygen supply leads to overproduction of ROS. In ischemic tissues, numerous studies have established a direct role for ROS in oxidative damage to lipids, proteins, and nucleic acids. Thus, mitochondria are both the initiator and the first target of oxidative stress. Mitochondrial damage can lead to cell death, given the role for mitochondria in energy metabolism and calcium homeostasis, as well as the ability of mitochondria to release pro-apoptotic factors such as cytochrome C and apoptosis-inducing factor (AIF). This review discusses possible mitochondrion-targeted strategies for preventing ROS-induced injury during reperfusion. The sequence of events that follow oxidative damage provides the outline for the review: thus, we will discuss protection of oxidative phosphorylation, mitochondrial membrane integrity and fluidity, and antioxidant or mild-uncoupling strategies for diminishing ROS production. Among mechanisms of action, we will describe the modulation of mitochondrial permeability transition pore (MPTP) opening, which may not only operate as a physiological Ca2+ release mechanism, but also contribute to mitochondrial deenergization, release of pro-apoptotic proteins, and protection by ischemic preconditioning (IPC). Finally, we will review genetic strategies for controlling apoptotic protein expression, stimulating mitochondrial oxidative defences, and increasing mitochondrial proliferation.

14 February 1998 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
APAlessandra Pagliara
Alessandra Pagliara
BTBernard Testa
Bernard Testa
PCPierre-Alain Carrupt
Pierre-Alain Carrupt
PJPascale Jolliet
Pascale Jolliet
CMChristophe Morin
Christophe Morin
JRJean-Pierre Rihoux
Jean-Pierre Rihoux

1 June 1996 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
SUSaïk Urien
Saïk Urien
JBJérôme Barré
Jérôme Barré
CMChristophe Morin
Christophe Morin
APAnne Paccaly
Anne Paccaly
GMGuy Montay
Guy Montay
JTJean-Paul Tillement
Jean-Paul Tillement

1 May 2001 in Brain Research
Verified
Journal Article
Closed access
ACAnne Cormier
Anne Cormier
CMChristophe Morin
Christophe Morin
RZRoland Zini
Roland Zini
JTJean-Paul Tillement
Jean-Paul Tillement
GLGilbert Lagrue
Gilbert Lagrue

1 January 1999
Verified
Journal Article
Closed access
RZR Zini
R Zini
CMChristophe Morin
Christophe Morin
ABA Bertelli
A Bertelli
ABA A Bertelli
A A Bertelli
JTJ P Tillement
J P Tillement

1 April 2003 in Neuropharmacology
Verified
Journal Article
Closed access
ACA Cormier
A Cormier
CMChristophe Morin
Christophe Morin
RZR Zini
R Zini
JTJ.-P Tillement
J.-P Tillement
GLG Lagrue
G Lagrue